Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO ^® capsules; 2.3 mg, 3 mg, and 4 mg)].

Autor: Machida M; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited., Fukunaga S; Oncology Clinical Research Department, Oncology Therapeutic Area Unit for Japan & Asia, Takeda Pharmaceutical Company Limited., Hara T; Innovation Promotion, Shonan Research Central Office, Research, Takeda Pharmaceutical Company Limited.

Publikováno v: Nihon yakurigaku zasshi. Folia pharmacologica Japonica [Nihon Yakurigaku Zasshi] 2018; Vol. 151 (4), pp. 166-178.